Literature DB >> 26207207

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study.

Kazushi Yoshida1, Yasuhide Yamada1.   

Abstract

Entities:  

Year:  2015        PMID： 26207207      PMCID： PMC4483483          DOI： 10.3978/j.issn.2218-6751.2015.03.04

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  5 in total

1.  Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma.

Authors:  Kazuo Kasahara; Tokuzo Arao; Kazuko Sakai; Kazuko Matsumoto; Asao Sakai; Hideharu Kimura; Takashi Sone; Atsushi Horiike; Makoto Nishio; Tatsuo Ohira; Norihiko Ikeda; Takeharu Yamanaka; Nagahiro Saijo; Kazuto Nishio
Journal:  Clin Cancer Res       Date:  2010-08-02       Impact factor: 12.531

2.  Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.

Authors:  Leonard B Saltz; Heinz-Josef Lenz; Hedy L Kindler; Howard S Hochster; Scott Wadler; Paulo M Hoff; Nancy E Kemeny; Ellen M Hollywood; Mithat Gonen; Marcus Quinones; Meroe Morse; Helen X Chen
Journal:  J Clin Oncol       Date:  2007-09-17       Impact factor: 44.544

Review 3.  Biology of interactions: antiepidermal growth factor receptor agents.

Authors:  Paul M Harari; Gregory W Allen; James A Bonner
Journal:  J Clin Oncol       Date:  2007-09-10       Impact factor: 44.544

4.  Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

Authors:  Takashi Seto; Terufumi Kato; Makoto Nishio; Koichi Goto; Shinji Atagi; Yukio Hosomi; Noboru Yamamoto; Toyoaki Hida; Makoto Maemondo; Kazuhiko Nakagawa; Seisuke Nagase; Isamu Okamoto; Takeharu Yamanaka; Kosei Tajima; Ryosuke Harada; Masahiro Fukuoka; Nobuyuki Yamamoto
Journal:  Lancet Oncol       Date:  2014-08-27       Impact factor: 41.316

5.  Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway.

Authors:  K Clarke; K Smith; W J Gullick; A L Harris
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640
  5 in total
  5 in total

1.  [Review on the Combination Strategy of Anti-angiogenic Agents 
and Other Anti-tumor Agents in Advanced Non-small Cell Lung Cancer].

Authors:  Ziyi Xu; Junling Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-05-20

Review 2.  EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer.

Authors:  Xueli Nan; Chao Xie; Xueyan Yu; Jie Liu
Journal:  Oncotarget       Date:  2017-08-09

3.  Three-Dimensional Convolutional Neural Network-Based Prediction of Epidermal Growth Factor Receptor Expression Status in Patients With Non-Small Cell Lung Cancer.

Authors:  Xuemei Huang; Yingli Sun; Mingyu Tan; Weiling Ma; Pan Gao; Lin Qi; Jinjuan Lu; Yuling Yang; Kun Wang; Wufei Chen; Liang Jin; Kaiming Kuang; Shaofeng Duan; Ming Li
Journal:  Front Oncol       Date:  2022-02-02       Impact factor: 6.244

Review 4.  Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence.

Authors:  Xiaochun Wang; David Goldstein; Philip J Crowe; Jia-Lin Yang
Journal:  Onco Targets Ther       Date:  2016-09-06       Impact factor: 4.147

5.  Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma.

Authors:  Yang Liu; Zhi-Cheng Xiong; Xin Sun; Li Sun; Shu-Ling Zhang; Jie-Tao Ma; Cheng-Bo Han
Journal:  Transl Cancer Res       Date:  2019-09       Impact factor: 1.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.